The way SARS-CoV-2 mutates in immunocompromised patients to escape Paxlovid could help chemists design better drugs that are more difficult for the virus to sidestep.
Columbia researchers have found why babies are susceptible to repeated bouts of common respiratory infections—but also have a unique weapon to fight off new pathogens that healthy adults lack.
Patients with mpox who were treated with the antiviral drug tecovirimat had similar outcomes regardless of HIV status, find researchers at Columbia University and Weill Cornell Medicine.